骨标志物在乳腺癌骨转移诊断与疗效观察中的作用

doi:10.3969/j.issn.1002-3070.2012.05.007

实用肿瘤学杂志 ›› 2012, Vol. 26 ›› Issue (5): 414-417.doi: 10.3969/j.issn.1002-3070.2012.05.007

骨标志物在乳腺癌骨转移诊断与疗效观察中的作用

迟伟群¹, 王福莉², 隋晓凤¹, 于晓斐¹, 张超民¹, 姚玉虹¹

1.哈尔滨医科大学附属第四医院检验科(哈尔滨 150001);
2.哈尔滨市第五医院

收稿日期:2012-03-20 出版日期:2012-05-25 发布日期:2012-10-29
通讯作者: 迟伟群,E-mail:junyang419@163.com
作者简介:迟伟群,男,(1977- ),硕士,主管技师,从事免疫学检验工作
基金资助:
黑龙江省卫生厅项目(2010-121)

The effectiveness of bone marker in the diagnosing and observing therapeutic effect of bone metastatic carcinoma

CHI Weiqun¹,WANG Fuli²,SUI Xiaofeng¹,YU Xiaofei¹,ZHANG Chaomin¹,YAO Yuhong¹

1.Department of Clinical Lab,The Fourth Affiliated Hospital of Harbin Medical University,Harbin 150001,China;
2.The Fifth Hospital of Harbin

Received:2012-03-20 Online:2012-05-25 Published:2012-10-29

摘要/Abstract

摘要： 目的探讨I型胶原交联羧基氨基端肽(β-Cross Laps)和总骨1型前胶原氨基端延长肽(P1NP)在乳腺癌骨转移诊断与疗效观察中的临床价值。方法运用电化学发光法对β-Cross Laps、P1NP、CA15-3进行定量检测。57例乳腺癌骨转移患者按转移灶多少分为2组,分别为骨显像轻度异常组(Ⅰ组)36例与骨显像明显异常组(Ⅱ组)21例。结果骨转移组β-Cross Laps、P1NP两种血清标志物较无骨转移组与对照组明显升高,差异具有统计学意义(P＜0.01),且治疗后两种指标明显低于治疗前水平(P＜0.05),随转移灶增加两种标志物水平也有升高趋势,差异具有统计学意义(P＜0.01)。而各组间及治疗前后CA15-3无显著变化(P＞0.05)。骨标志物β-Cross Laps、P1NP对乳腺癌骨转移的诊断灵敏度分别达到71.25%与64.05%,特异性分别达到88.00%与81.99%,均高于骨显像所显示结果的50.32%和61.17%。结论血清骨标志物β-Cross Laps、P1NP水平可以反映乳腺癌骨转移患者病情变化,并可以运用于疗效监测,有较好的临床应用价值。

关键词: I型胶原交联羧基氨基端肽, 总骨1型前胶原氨基端延长肽, 乳腺癌骨转移

Abstract: Objective To investigate the clinical value of β-Cross Laps and P1NP in diagnosing and observing therapeutic effect of bone metastatic carcinoma.Methods Detecting β-Cross Laps、P1NP、CA15-3 quantitatively using the electrochemiluminescence.All the 57 patient with bone metastatic carcinoma were divided into two grouos.One(Ⅰ)for 36 were with lighter abnormality of bone imaging.The other(Ⅱ)were remarkableness of bone imaging.Results The concentrations of β-Cross Laps and P1NP in the group one are obviously higher than the group two and control group.The discrepancy have the statistical significance(P＜0.01).And the concentrations of the two marker aftertherapy are also obviously lower than the concentrations before therapy(P＜0.05),the concentrations of the two marker are also having the increasing tendency followed by the creasing of metastasis.The discrepancy have the statistical significance(P＜0.01).There are no significantly changes of CA15-3 in different groups(P＞0.05).The sensibility of β-Cross Laps and P1NP might reached at 71.25% and 64.05%.The specificity of them might reached at 88.0% and 81.99%.Both are higher than the results of bone imaging for 50.32% and 61.17%.Conclusion The concentrations of β-Cross Laps and P1NP might reflect the alleosis of the patients of bone metastatic carcinoma.It can be used for monitoring therapeutic effect,having better clinical application worth.

Key words: β-Cross Laps, P1NP, Bone metastatic carcinoma

中图分类号:

R737.9

迟伟群, 王福莉, 隋晓凤, 于晓斐, 张超民, 姚玉虹. 骨标志物在乳腺癌骨转移诊断与疗效观察中的作用[J]. 实用肿瘤学杂志, 2012, 26(5): 414-417.

CHI Weiqun,WANG Fuli,SUI Xiaofeng,YU Xiaofei,ZHANG Chaomin,YAO Yuhong. The effectiveness of bone marker in the diagnosing and observing therapeutic effect of bone metastatic carcinoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(5): 414-417.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[3]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[4]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[5]	白玉贤, 马仲娟, 苏颖玲, 慕安国, 谢蕊. 胃癌患者FHIT、hMLH1、p16、RAR-beta、Reprimo和TIMP3基因的甲基化研究[J]. 实用肿瘤学杂志, 2019, 33(1): 8-13.
[6]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[7]	何煦, 叶尚勉, 董丹丹, 李科. HLA-G在乳腺癌中的表达及意义[J]. 实用肿瘤学杂志, 2018, 32(5): 410-414.
[8]	王志, 刘忠卫, 曾雪芸, 隋明洁, 廖静怡, 李月欢, 黄卫东, 刘国祥. 基于EQ-5D-5L的结直肠癌癌前病变患者健康相关生命质量研究[J]. 实用肿瘤学杂志, 2018, 32(4): 320-326.
[9]	范宁宁, 耿敬姝. 长链非编码RNA MEG3在人胶质瘤细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(3): 219-223.
[10]	闫石, 霍明鸣, 庞慧, 李焱, 蔡莉. p53对绝经后HR阳性、HER-2阳性术后乳腺癌患者内分泌药物疗效的预测价值[J]. 实用肿瘤学杂志, 2018, 32(3): 234-213.
[11]	李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.
[12]	靳俊杰, 安静, 曹涤非, 宋爱利, 赵丽丽, 刘兆良. 组蛋白赖氨酸转移酶KAT6B基因shRNA慢病毒载体的构建与鉴定[J]. 实用肿瘤学杂志, 2018, 32(1): 1-6.
[13]	郑伟, 许守平, 庞达. 长链非编码RNA Linc00152在泛癌中表达、预后及功能研究[J]. 实用肿瘤学杂志, 2018, 32(1): 7-13.
[14]	殷玉莲, 张卫红, 周悦, 叶媚娜, 陈红风. ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究[J]. 实用肿瘤学杂志, 2018, 32(1): 14-18.
[15]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.

骨标志物在乳腺癌骨转移诊断与疗效观察中的作用

The effectiveness of bone marker in the diagnosing and observing therapeutic effect of bone metastatic carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价